title: A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
abstract: BACKGROUND
  The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma.
  
  
  METHODS
  The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction.
  
  
  RESULTS
  Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells.
  
  
  CONCLUSIONS
  The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53.
  
  
  CONCLUSIONS
  The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer.
authors: Divison of Translational Research for Biologics, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Hiroki
authors: H
authors: Saito
authors: Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan.
authors: Satoshi
authors: S
authors: Ando
authors: Divison of Translational Research for Biologics, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Naoya
authors: N
authors: Morishita
authors: Department of Biochemistry, Korea University College of Medicine, Seoul, Republic of Korea.
authors: Kyung-Mi
authors: KM
authors: Lee
authors: Department of Urology, National Kidney and Transplantation Institute, Quezon City, Philippines.
authors: Dante
authors: D
authors: Dator
authors: St. Luke's Medical Center, Global City, Philippines.
authors: David
authors: D
authors: Dy
authors: Division of Urology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Katsumi
authors: K
authors: Shigemura
authors: Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Zainal
authors: Z
authors: Adhim
authors: Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Ken-Ichi
authors: K
authors: Nibu
authors: Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Masato
authors: M
authors: Fujisawa
authors: Divison of Translational Research for Biologics, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan Division of Urology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan toshiro@med.kobe-u.ac.jp.
authors: Toshiro
authors: T
authors: Shirakawa
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D058851:GPI-Linked Proteins / Q000096:biosynthesis / Q000235:genetics; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D016219:Immunotherapy, Adoptive / Q000379:methods*; D047908:Intracellular Signaling Peptides and Proteins / Q000096:biosynthesis / Q000235:genetics; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D000077195:Squamous Cell Carcinoma of Head and Neck; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: D058851:GPI-Linked Proteins; D047908:Intracellular Signaling Peptides and Proteins; D012333:RNA, Messenger; C495901:TP53 protein, human; D014409:Tumor Necrosis Factor-alpha; D016159:Tumor Suppressor Protein p53; C423231:ULBP1 protein, human
keywords: Ad-p53 gene therapy; LAK immunotherapy; TNF-a; head neck squamous cell carcinoma